We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva's Trisenox Gets FDA Approval as First-Line Treatment
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has approved the label expansion of Trisenox injection to include first-line treatment of acute promyelocytic leukemia (“APL”) patients in combination with tretinoin.
The eligible APL patients should have t(15;17) translocation or PML/RAR-alpha gene expression.
Trisenox is currently approved for a similar indication in patients who are refractory/relapsed to retinoid and anthracycline chemotherapy.
The drug is already approved in the EU as both first-line and second-line treatment for this indication.
Teva’s shares have declined 35% in the past year, underperforming the industry’s decline of 19% in that period.
According to the company, Trisenox, in combination with retinoic acid, can increase survival rates, dramatically reduce the risk of relapse, and help avoid chemotherapy-related side effects in low-to-intermediate risk APL patients. It has been seen in clinical studies that Trisenox, in combination with retinoic acid, can lead to a 99% overall survival rate with almost no relapse after more than four years (50 months) of median follow-up.
Teva’s oncology portfolio includes five drugs, which performed well in the third quarter of 2017. It registered year-over-year growth of 12% to reach $302 million. The label expansion of Trisenox is expected to further boost the portfolio’s performance in the coming quarters.
However, Teva is facing headwinds due to pricing pressure in the generics industry. Also, the approval of Mylan’s generic version of its key drug, Copaxone, in October last year had a negative impact on its fourth quarter revenue guidance.
Moreover, the Israeli firm is also facing a huge debt load, which swelled with the acquisition of Allergan’s generic division in 2016.
In a bid to get rid of its problems, the company brought in a new chief executive officer (“CEO”), Kare Schultz, who had played an instrumental role in the turnaround of Denmark’s H. Lundbeck A/S, which was struggling with a string of losses. He also worked as the chief operating officer of another Denmark based drug giant, Novo Nordisk A/S (NVO - Free Report) .
The new CEO announced restructuring plans in December 2017 in order to reduce cost and improve business performance, profitability, cash flow generation and productivity. Teva has announced to cut about 14,000 job cuts (more than 25% of the company’s global workforce) over the next two years with the majority expected in 2018. The company will also shut down many of its offices and R&D facilities around the globe and divest the assets. The moves are expected to reduce its $16.1 billion cost base (estimated for 2017) by $3 billion at the end of 2019.
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Teva's Trisenox Gets FDA Approval as First-Line Treatment
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has approved the label expansion of Trisenox injection to include first-line treatment of acute promyelocytic leukemia (“APL”) patients in combination with tretinoin.
The eligible APL patients should have t(15;17) translocation or PML/RAR-alpha gene expression.
Trisenox is currently approved for a similar indication in patients who are refractory/relapsed to retinoid and anthracycline chemotherapy.
The drug is already approved in the EU as both first-line and second-line treatment for this indication.
Teva’s shares have declined 35% in the past year, underperforming the industry’s decline of 19% in that period.
According to the company, Trisenox, in combination with retinoic acid, can increase survival rates, dramatically reduce the risk of relapse, and help avoid chemotherapy-related side effects in low-to-intermediate risk APL patients. It has been seen in clinical studies that Trisenox, in combination with retinoic acid, can lead to a 99% overall survival rate with almost no relapse after more than four years (50 months) of median follow-up.
Teva’s oncology portfolio includes five drugs, which performed well in the third quarter of 2017. It registered year-over-year growth of 12% to reach $302 million. The label expansion of Trisenox is expected to further boost the portfolio’s performance in the coming quarters.
However, Teva is facing headwinds due to pricing pressure in the generics industry. Also, the approval of Mylan’s generic version of its key drug, Copaxone, in October last year had a negative impact on its fourth quarter revenue guidance.
Moreover, the Israeli firm is also facing a huge debt load, which swelled with the acquisition of Allergan’s generic division in 2016.
In a bid to get rid of its problems, the company brought in a new chief executive officer (“CEO”), Kare Schultz, who had played an instrumental role in the turnaround of Denmark’s H. Lundbeck A/S, which was struggling with a string of losses. He also worked as the chief operating officer of another Denmark based drug giant, Novo Nordisk A/S (NVO - Free Report) .
The new CEO announced restructuring plans in December 2017 in order to reduce cost and improve business performance, profitability, cash flow generation and productivity. Teva has announced to cut about 14,000 job cuts (more than 25% of the company’s global workforce) over the next two years with the majority expected in 2018. The company will also shut down many of its offices and R&D facilities around the globe and divest the assets. The moves are expected to reduce its $16.1 billion cost base (estimated for 2017) by $3 billion at the end of 2019.
Teva Pharmaceutical Industries Limited Price
Teva Pharmaceutical Industries Limited Price | Teva Pharmaceutical Industries Limited Quote
Zacks Rank
Teva carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>